Macquarie Group Ltd. cut its position in shares of Boston Scientific Corp. (NYSE:BSX) by 24.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 696,195 shares of the company’s stock after selling 225,450 shares during the period. Macquarie Group Ltd. owned about 0.05% of Boston Scientific Corp. worth $16,270,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in Boston Scientific Corp. by 116.4% in the second quarter. JPMorgan Chase & Co. now owns 45,873,864 shares of the company’s stock worth $1,072,070,000 after buying an additional 24,672,937 shares during the last quarter. Eaton Vance Management raised its position in Boston Scientific Corp. by 14,198.2% in the second quarter. Eaton Vance Management now owns 3,907,561 shares of the company’s stock worth $91,320,000 after buying an additional 3,880,232 shares during the last quarter. BlackRock Investment Management LLC raised its position in Boston Scientific Corp. by 98.3% in the second quarter. BlackRock Investment Management LLC now owns 7,165,917 shares of the company’s stock worth $167,467,000 after buying an additional 3,552,349 shares during the last quarter. Marshall Wace LLP raised its position in Boston Scientific Corp. by 1,748.3% in the second quarter. Marshall Wace LLP now owns 3,258,892 shares of the company’s stock worth $76,159,000 after buying an additional 3,082,574 shares during the last quarter. Finally, Columbus Circle Investors bought a new position in Boston Scientific Corp. during the second quarter worth about $64,918,000. 89.96% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Boston Scientific Corp. (NYSE:BSX)

Shares of Boston Scientific Corp. (NYSE:BSX) traded down 1.75% during midday trading on Monday, reaching $20.78. The company’s stock had a trading volume of 5,074,921 shares. The stock has a market capitalization of $28.30 billion, a PE ratio of 392.08 and a beta of 1.15. The stock has a 50-day moving average price of $22.11 and a 200 day moving average price of $23.08. Boston Scientific Corp. has a 52 week low of $15.67 and a 52 week high of $24.79.

Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 26th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. Boston Scientific Corp. had a net margin of 0.99% and a return on equity of 23.25%. The firm had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the prior year, the company posted $0.24 earnings per share. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. Equities analysts forecast that Boston Scientific Corp. will post $1.10 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Macquarie Group Ltd. Sells 225,450 Shares of Boston Scientific Corp. (BSX)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/28/macquarie-group-ltd-sells-225450-shares-of-boston-scientific-corp-bsx.html.

BSX has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 31st. Citigroup Inc. upped their price objective on Boston Scientific Corp. from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, August 3rd. Argus raised Boston Scientific Corp. from a “hold” rating to a “buy” rating and upped their price objective for the stock from $23.82 to $33.00 in a report on Thursday, September 1st. They noted that the move was a valuation call. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Boston Scientific Corp. in a report on Friday, October 14th. Finally, Evercore ISI reaffirmed a “buy” rating and set a $26.00 price objective (up previously from $25.50) on shares of Boston Scientific Corp. in a report on Sunday, July 31st. Five equities research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. Boston Scientific Corp. currently has an average rating of “Buy” and a consensus price target of $25.70.

Boston Scientific Corp. Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Receive News & Stock Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related stocks with our FREE daily email newsletter.